Intervacc : Strangvac, a vaccine against equine strangles, has been granted marketing authorisation by the European Commission

Stockholm, August 16, 2021 - Intervacc AB ("Intervacc") announced today that the European Commission has granted a Marketing Authorisation for Strangvac within the European Union. Strangvac is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally.

"We are happy that Strangvac has received the European Commission's approval" explainedAndreas Andersson, CEO of Intervacc. "Strangvac is the first Swedish Animal Health vaccine to be approved through the centralised procedure and we feel great responsibility to spread the use the vaccine to improve the health of horses across the European Union."

"Strangvac does not contain any live bacteria and is given to horses by intramuscular injection," continued Emma Hartman, DVM and global product manager for the vaccine. "Vaccination generates an immune response against several different proteins from the bacteria Streptococcus equi, which causes strangles, but does not trigger any of the available diagnostic tests for strangles, so it can be used alongside current strategies as an important tool to reduce the impact of this devastating disease."

"The approval of Strangvac for use in Europe is a breakthrough for this new generation of vaccines", explains Dr Tim Wood, Head of CMC and Regulatory at Intervacc. "The proteins in Strangvac can simultaneously target several disease-causing mechanisms in a very selective manner. In the future, this technology has terrific potential to prevent many different diseases of animals."

"Strangles is endemic in horse populations throughout the world and causes incalculable suffering, stress and economic cost to the equine industry within Europe" added Dr Andrew Waller, Chief Scientific Officer at Intervacc. "The development of Strangvac has been achieved in partnership with world-leading scientists at the Karolinska Institute and the Swedish University of Agricultural Sciences. We are excited about applying this ground-breaking science to prevent such an important disease of horses."

For more information please contact:                           

Andreas Andersson, CEO

Phone: [phone], cell [phone]
E-mail: [e-mail]

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 16, 2021.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, [e-mail], [phone] as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [e-mail], Phone: +46 (0)8 - 684 211 10

https://news.cision.com/intervacc/r/strangvac--a-vaccine-against-equine-strangles--has-been-granted-marketing-authorisation-by-the-europ,c3397186

https://mb.cision.com/Main/4632/3397186/1454677.pdf

https://news.cision.com/intervacc/i/lntervacc-,c2943626

https://news.cision.com/intervacc/i/ceo-andreas-andersson,c2943627

(c) 2021 Cision. All rights reserved., source Press Releases - English